- Home
- DIAX vs EVMN Comparison
DIAX vs EVMN Comparison
Compare DIAX & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DIAX | EVMN |
|---|---|---|
| Founded | 2005 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.9M | 892.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DIAX | EVMN |
|---|---|---|
| Price | $14.49 | $21.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $44.17 |
| AVG Volume (30 Days) | 130.1K | ★ 386.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.42 | $13.89 |
| 52 Week High | $15.85 | $33.20 |
Technical Indicators
Market Signals| Indicator | DIAX | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 24.14 | 41.90 |
| Support Level | $14.49 | $15.25 |
| Resistance Level | $14.97 | $23.08 |
| Average True Range (ATR) | 0.21 | 2.25 |
| MACD | -0.08 | -0.80 |
| Stochastic Oscillator | 2.20 | 8.28 |
Price Performance
Historical ComparisonAbout DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.